Prior Auth Required

10063 - nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016 Dec 17; 388( ):3017

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Servicenusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016 Dec 17; 388( ):3017
Procedure / Service Description

Updated Accessed - 1 Spinraza [prescribing information]. Cambridge, MA; Biogen. April 2024. 4/24 7/24 2 Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with 12/16 3/23 nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016 Dec 17; 388(10063):3017- 3026. 3 Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal 11/17 3/23

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.